B. Riley Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

B. Riley Securities analyst Kalpit Patel has maintained a 'Buy' rating on ArriVent BioPharma (NASDAQ: AVBP) and increased the price target from $37 to $45. This adjustment reflects a positive outlook for the company's stock performance.